Orally active isoxazoline GPIIb/IIIa antagonists

Cardiovascular Drug Reviews

Volumn 16, Issue 1, 1998, Pages 48-61

  Mousa, Shaker A ^a   Wityak, John ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Antiplatelet drugs; Antithrombotic drugs; DMP754; DMP802; GPIIb IIIa receptor; Integrins; XR300

Indexed keywords

2 AMINO 3 [2 [3 (4 FORMAMIDINOPHENYL) 2 ISOXAZOLIN 5 YL]ACETAMIDO]PROPIONIC ACID; 2 AMINO 3 [2 [3 (4 FORMAMIDINOPHENYL) 2 ISOXAZOLIN 5 YL]ACETAMIDO]PROPIONIC ACID ETHYL ESTER; 3 [[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETAMIDO] N [(3,5 DIMETHYL 4 ISOXAZOLYL)SULFONYL]ALANINE; 3 [[[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETYL]AMINO] N (BUTOXYCARBONYL)ALANINE; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; ISOXAZOLINE DERIVATIVE; ROXIFIBAN; TICLOPIDINE; UNCLASSIFIED DRUG;

ANGIOPLASTY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR BLOCKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0031856736     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1998.tb00344.x     Document Type: Article

References (51)

1. Alig L, Edenhofer A, Hadváry P, et al. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992;35:4393-4407.
2. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Platelets Health Dis 1990;4:1-26.
3. Askew BC, McIntyre CJ, Hunt CA, et al. Nonpeptide glycoprotein IIb/IIIa Inhibitors. 13. Design and synthesis of an orally active pyrazolopiperazinone nonpeptide fibrinogen receptor antagonist. Bioorg Med Chem Lett 1997;7:865-870.
4. Bach II AC, Eyermann CJ, Gross JD, et al. Structural studies of a family of high affinity ligands for GPIIb/IIIa. J Am Chem Soc 1994;116:3207-3219.
5. Brashear KM, Cook JJ, Bednar B, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors: 18. Indole alpha-sulfonamide acids are potent inhibitors of platelet aggregation. Bioorg Med Chem Lett 1997;7:2793-2798.
6. 7 mimetic for the predicted γ-turn conformation found in several constrained RGD antagonists. J Med Chem 1992;35:3970-3972.
7. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986;68:783-786.
8. Cook NS, Kottirsch G, Zerwes H-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future 1994;19:135-159.
9. Davies MJ, Thomas AC. Plaque fissuring - The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985;53:363-373.
10. D'Souza SE, Ginsberg MH, Burke TA, Plow EF. The ligand binding site of the platelet integrin receptor GPIIb/IIIa is proximal to the second calcium binding domain of its a subunit. J Biol Chem 1990;265:3440-3446.
11. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
12. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-989.
13. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol 1985;5:175B-184B.
14. Gold HK, Torres FW, Garabedian HD, et al. Evidence of a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patient with unstable angina. J Am Coll Cardiol 1993;21:1029-1047.
15. Hamm CW, Bliefield W, Kupper W, Lorenz RL, Weber PC, Wober W. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987;10:998-1004.
16. Hartman GD, Egbertson MS, Halczenko W, et al. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J Med Chem 1992;35:4640-4642.
17. Hirschmann R, Sprengeler PA, Kawasaki T, Leahy JW, Shakespeare WC, Smith III AB. The first design and synthesis of a steroidal peptidomimetic. The potential value of peptidomimetics in elucidating the bioactive conformation of peptide ligands. J Am Chem Soc 1992;114:9699-9701.
18. Jackson S, DeGrado W, Dwivedi A, et al. Template-constrained cyclic peptides: Design of high-affinity ligands for GPIIb/IIIa. J Am Chem Soc 1994;116:3220-3230.
19. Kapil R, Emm T, Mousa S, Padovani P, Quon C, Lam G. Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel antiplatelet agent, XU063, in beagle dogs. Thromb Res 1997;86: 221-232.
20. Kleiman NS, Ohman E, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993;22:381-389.
21. Kottirsch G, Tapparelli C, Zerwes H-G. Fibrinogen receptor antagonists containing a gamma-lactam Gly-Asp isostere. Bioorg Med Chem Lett 1993;3:1675-1680.
22. Kottke-Marchant K, Simpfendorfer C, Lowrie M, Burns D, Anders RJ. Sustained but variable inhibition of platelet aggregation with xemlofiban, an oral GPIIb/IIIa receptor antagonist, in patients with unstable angina. Circulation (Suppl. 8) 1995;92:I488.
23. Ku TW, Ali FE, Barton LS, Bean JW, Bondinell WE, Burgess JL, et al. Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained RGD peptide. J Am Chem Soc 1993;115:8861-8862.
24. Mousa S, Bozarth J, Forsythe M, et al. Antiplatelet efficacy and specificity of a novel platelet GPIIb/IIIa receptor antagonist, DMP728. Cardiology 1993;83:374-382.
25. Mousa S, Bozarth J, Forsythe M, et al. Antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation 1994;89:3-12.
26. Mousa SA, Forsythe M, Lorelli W, et al. Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP 754: Receptor binding affinity and specificity. Coron Artery Dis 1996;7:767-774.
27. Mousa S, Forsythe M, Wityak J, Bozarth J, Lorelli W, Mu D. Antiplatelet/antithrombotic efficacy and specificity of XR300, a novel non-peptide platelet GPIIb/IIIa antagonist. J Cardiovasc Pharmacol 1998; 31:1-9.
28. Mousa S, Mayo MC, Bozarth JM, Forsythe MS, Reilly TM. Antiplatelet effects of thrombin inhibitors versus GPIIb/IIIa receptor antagonists: Comparative kinetic and mechanistic analysis. Thromb Haemost 1993;69:1321.
29. Mousa S, Mu D-X, Reilly T. Intravenous and oral antithrombotic efficacy of a novel non-peptide antiplatelet GPIIb/IIIa antagonist, DMP754 as compared to other antiplatelet & anticoagulant strategies. Thromb Haemost (Suppl) 1997;1600:392.
30. Mousa S, Olson RE, Bozarth JM, et al. Oral antiplatelet efficacy and specificity of a novel non-peptide platelet GPIIb/IIIa receptor antagonist, DMP 802. J Cardiovasc Pharmacol 1998 (in press).
31. Mousa S, Topol E. Novel antiplatelet therapies: Recent advances in the development of platelet GPIIb/IIIa receptor antagonists. In: Surruys PW, Holmes D, eds. Current review of interventional cardiology, Third Edition. Philadelphia: Current Medicine, 1997;13:114-129.
32. Narjes H, Weisenberger H, Muller TH, et al. Tolerability and platelet fibrinogen receptor occupancy (FRO) after oral treatment with BEBU 104 xx in healthy volunteers. Thromb Haemost 1995;73:1315.
33. Nichols AJ, Ruffolo RR, Huffman WF, Poste G, Samanen J. Development of GPIIb/IIIa antagonists as antithrombotic drugs. Trends Pharmacol Sci 1992;13:413-417.
34. O'Neil K, De Grado W, Mousa S, Ramachandran N, Hoess R. Identification of recognition sequences of adhesion molecules using phage display technology. Meth Enzymology 1994;245:370-386.
35. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993;88:1512-1517.
36. Philips DR, Charo IF, Scarborough RM. GPIIb/IIIa: The responsive integrin. Cell 1991;65:359-362.
37. Prugh JD, Gould RJ, Lynch RJ, et al. Nonpeptide GPIIb/IIIa Inhibitors. 16. Thieno[2,3-b]thiophene a-sulfonamides are potent inhibitors of platelet aggregation. Bioorg Med Chem Lett 1997;7:865-870.
38. Pytela R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: Member of a family of RGD specific adhesion receptors. Science 1986;231:1559-1562.
39. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker, Integrelin, in elective coronary intervention. Circulation 1995;91:215-217.
40. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-1764.
41. Theroux P, Waters D, Lam J, Junean M, McCans J. Reactivation of unstable angina after discontinuation of heparin. New Engl J Med 1992;327:141-145.
42. Topol EJ. Novel antithrombotic approaches to coronary artery diseases. Am J Cardiol 1995;75:27b-33b.
43. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994;343:881-886.
44. Topol EJ, Plow EF. Clinical trials of platelet receptor inhibitors. Thromb Haemost 1993;70:94-98.
45. Wagner G, Horn H, Richter P, Vieweg H, Lischke I, Kazmirowski H.-G. Synthesis of antiproteolytically active Na-sulfonylated amidinophenylalaninamides. Pharmazie 1981;36:597-603.
46. Weller T, Alig L, Hürzeler Müller M, Kouns WC, Steiner B. Fibrinogen receptor antagonists - A novel class of promising antithrombotics. Drugs Future 1994;19:461-476.
47. Wityak J, Sielecki TM, Pinto DJ, et al. The discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists. J Med Chem 1997;40:50-60.
48. Xue C-B, Wityak J, Sielecki TM, et al. Discovery of an orally active series of isoxazoline GPIIb/IIIa antagonists. J Med Chem 1997;40:2064-2084.
49. Yasuda T, Gold HK, Fallon JT, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988;81:1284-1291.
50. Zablocki JA, Miyano M, Rao SN, Panzer-Knodle S, Nicholson N, Feigen L. Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor. J Med Chem 1992;35:4914-4817.
51. Zablocki JA, Miyano M, Garland RB, et al. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX and the platelet GP IIb-IIIa receptor. J Med Chem 1993;36:1811-1819.